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ABSTRACT
The presumed superiority of renin–angiotensin–aldosterone
system (RAAS)-blocking agents over other antihypertensive
agents in patients with diabetes to delay development of end-
stage kidney disease (ESKD) has recently been challenged. In
addition, there is ongoing uncertainty whether RAAS-blocking
agents reduce mortality and/or delay ESKD in patients with dia-
betes and chronic kidney disease (CKD) stages 3–5. In this sub-
group, there might be an expedited need for renal replacement
therapy (RRT) when RAAS-blocking agents are used. We con-
ducted a meta-analysis of randomized controlled trials (RCTs)
of at least 6-months duration in adult patients with diabetes
who also have non-dialysis CKD stages 3–5. RCTs comparing
single RAAS-blocking agents to placebo or alternative antihy-
pertensive agents were included. Outcomes of interest were all-
cause mortality, cardiovascular morbidity, progression of renal
function, ESKD and adverse events. A total of nine trials
(n¼ 9797 participants with CKD stages 3–5) ﬁt our inclusion
criteria. There was no difference between the RAAS group and
control group regarding all-cause mortality {relative risk
[RR]¼ 0.97 [95% conﬁdence interval (CI) 0.85–1.10]}, cardio-
vascular mortality [RR¼ 1.03 (95% CI 0.75–1.41)] and adverse
events [RR¼ 1.05 (95% CI 0.89–1.25)]. There was a trend for a
favourable effect for non-fatal cardiovascular events [RR¼ 0.90
(95% CI 0.81–1.00)] and a lower risk of the composite endpoint
need for RRT/doubling of serum creatinine [RR¼ 0.81 (95% CI
0.70–0.92)] in the RAAS-blocking agents group versus the con-
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|trol group. We found evidence that in patients with diabetes
mellitus and CKD stages 3–5, treatment with RAAS-blocking
agents did not result in a clear survival advantage. The effect on
renal outcomes did depend on the selected outcome measure.
However, we did not ﬁnd evidence that the use of RAAS-
blocking agents expedited the need for RRT in patients with
CKD stages 3–5.
Keywords: angiotensin II, diabetes mellitus, diabetic kidney
disease, guidelines, predialysis
INTRODUCTION
Diabetes substantially reduces life expectancy, with cardiovas-
cular disease being the leading cause of mortality, accounting
for 50% of all causes of death [1–3]. The odds ratio of having
chronic kidney disease (CKD) for patients with versus without
(type 2) diabetes is 2.5; furthermore, at least 20% of patients
with diabetes mellitus (DM) have CKD stages 3–5 [4, 5]. The
combination of advanced CKD and diabetes is linked with
increased mortality, an association that is amplified as there is
progression to end-stage kidney disease (ESKD) [6].
Because of the presumed ability of angiotensin-converting en-
zyme inhibitors (ACEIs) and angiotensin II receptor blockers
(ARBs) to reduce at the same time all-cause mortality, cardiovas-
cular risk and progression of nephropathy, most current renal
and DM guidelines recommend ACEIs/ARBs as first-line drugs
for diabetic patients with CKD [1, 7]. However, several guideline
groups acknowledge that there are limitations in the evidence
base and therefore the evidence level is mostly rated as low or of
moderate quality [1, 7–9], particularly for CKD stages 3–5 [10–
12]. In fact, some small studies including populations with more
advanced CKD suggest that withholding renin–angiotensin–
aldosterone system (RAAS)-blocking agents may actually reverse
the decline in glomerular filtration rate (GFR) and retard the
start of renal replacement therapy (RRT) [13, 14]. Potential car-
diovascular protection may be counter balanced by the potential
worsening of renal function and the need to start RRT earlier. It
can also be questioned whether administering RAAS-blocking
agents to patients with already advanced cardiovascular and
renal damage will still result in a survival advantage.
A recent meta-analysis including only studies comparing
RAAS blockers to other antihypertensive agents did not support
an advantage for RAAS blockade with regard to total or cardio-
vascular mortality, nor for progression of CKD [15]. However,
this study did not focus on patients with advanced CKD. The
network meta-analysis of Palmer et al. [16] reported a protect-
ive effect of RAAS blockade, but the overwhelming majority of
this effect was due to studies comparing RAAS-blocking agents
to placebo. As such, this study was not really able to assess the
place of RAAS inhibitors as compared with other antihyperten-
sive agents. In addition, this study found a higher risk of hyper-
kalaemia in the RAAS inhibitor group, raising a potential
concern for the use of these drugs in patients with more
advanced CKD.
To answer these questions, we conducted a systematic review
and meta-analysis to investigate both hard and surrogate renal
and cardiovascular endpoints in patients with DM and CKD
stages 3–5 who were receiving any form of RAAS-blocking
treatment in a randomized controlled trial (RCT). Our specific
objective was to evaluate if there is a beneficial effect on cardio-
vascular events or mortality that exceeds potential renal adverse
events (decrease in GFR, expedited need for RRT and hyperka-
laemia events).
MATERIALS AND METHODS
Our systematic review included RCTs of at least 6months dur-
ation, comparing single RAAS-blocking agents (only ACEIs,
ARBs or renin inhibitors, but not in combination) with either
placebo or an alternative antihypertensive agent in patients with
DM and moderate or severe CKD [stages 3–5 or estimated glo-
merular filtration rate (eGFR)<45mL/min/1.73 m2]. We also
included studies presenting pre-planned post hoc analyses of
RCTs if they analysed a subgroup including our population of
interest and maintained the initial randomization frame or if
they provided an interaction analysis for patients with DM and
CKD stages 3b–5 as defined according to the Kidney Disease:
Improving Global Outcomes definition as abnormalities of kid-
ney structure or function present for >3months, with implica-
tions for health [17]. It was staged based on eGFR (mL/min/
1.73 m2) as follows: 45–59, stage 3a; 30–44, stage 3b; 15–29,
stage 4;< 15, stage 5 [17]. When different subgroups of patients
with advanced CKD were available, the data were extracted
only for those with eGFR< 45mL/min/1.73 m2.
We included all available studies that met the inclusion crite-
ria regarding the design, population and intervention, irrespect-
ive of the reported outcomes. We did not put restrictions on
language. Studies that included only participants on haemodi-
alysis (HD), peritoneal dialysis (PD) or renal transplant were
excluded, as well as studies with<30% of patients with DM, un-
less results were presented separately for our population of
interest or an interaction analysis was provided. The primary
analysis was performed once with studies comprising both pa-
tients with and without DM (overall) and once with studies
including only patients with DM. Also, several subgroup ana-
lyses were performed for studies with placebo treatment versus
with other antihypertensive treatment in the control arm, for
studies with or without high risk of bias or for studies stratified
by type of RAAS-blocking agent (ACEI versus ARB).
Finally, meta-regression analysis was conducted to assess the
impact on the effect estimates of studies with <100% diabetes
patients for major outcomes of interest: all-cause mortality and
the composite outcome need for RRT/doubling of serum
creatinine.
Search strategy
Two reviewers searched MEDLINE (1950–November 2016),
Embase and Cochrane Central Register of Controlled Trials
(1991–November 2016) according to a standardized protocol
(see Supplementary Table S1 for search terms used in strategies
for this review) [18]. Citations identified from electronic data-
bases were supplemented by manually reviewing reference lists
of clinical practice guidelines, review articles and relevant
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|studies. Searches for available data in other sources of grey lit-
erature (abstracts, conference proceedings, unpublished studies,
databases of industrial companies, US Food and Drug
Administration or European Medicines Agency) was per-
formed. A first search for studies was run to January 2014 and
updated to November 2016 afterwards. When possible, we con-
tacted investigators of included trials to obtain missing or in-
complete data for key outcomes.
Data extraction, risk of bias and quality of evidence
Data extraction was performed independently by two re-
viewers (I.N., E.D.) using standard data extraction forms and
included in a database table; any disagreements between re-
viewers were resolved in consultation with a third reviewer
(A.C.).
Data on the characteristics of the trials, participants, inter-
ventions and hard and surrogate endpoints were extracted. We
planned that missing or unclear information would be searched
within the study protocol or within the original trial (for the
post hoc RCTs). Any full text in a language other than English
would be translated. As a significant proportion of the included
studies reported both cardiovascular and renal outcomes in a
pre-specified composite manner, data for the renal and cardio-
vascular outcomes of interest were extracted only from studies
that analysed these outcomes separately. When more than one
article for a study was found, we used only the references with
the most complete data, or both if they reported different types
of outcomes.
Risk of bias was explored according to the Cochrane
Handbook for Systematic Reviews of Interventions for the fol-
lowing domains: selection bias (random sequence generation,
allocation concealment), performance bias (blinding of the par-
ticipants and personnel), detection bias (blinding of assessment
of outcome), attrition bias (incomplete outcome data), report-
ing bias (selective reporting) and other bias (significant different
group comparisons, funding sources, early termination of a
trial) [19]. We considered trials to have a high selective report-
ing bias when data on all-cause and cardiovascular mortality
outcomes were not provided or were provided in an inadequate
manner (data that could not be included in a meta-analysis)
[19].
Quality of evidence was explored according to the Grading
of Recommendations Assessment, Development and
Evaluation (GRADE) Working Group for the following limita-
tions: study limitation [lack of concealment allocation, lack of
blinding, important loss to follow-up, no intention-to-treat
(ITT) analysis, early discontinuation of the trial, selective re-
porting], inconsistent results (heterogeneity or variability in re-
sults), indirectness of evidence (use of only one of two active
drugs, differences between populations/interventions/outcomes
of interest), imprecision (for trials including a relatively small
number of patients or events, wide confidence intervals) and
publication bias (failure of the investigators to report studies)
[20].
We evaluated the following types of outcome measures:
(i) All-cause mortality
(ii) Cardiovascular mortality
(iii) Non-fatal cardiovascular events
(iv) Renal outcomes:
• Dichotomous—evaluating the number of events:
need for RRT/doubling of serum creatinine or a
composite of these
• Continuous—changes from baseline values and end-
of-treatment values: serum creatinine (mg/dL), crea-
tinine clearance (CrCl) (mL/min/1.73 m2), eGFR
(mL/min/1.73 m2)
(v) Adverse events:
• Hypotension
• Hyperkalaemia
• Total number of reported adverse events
Statistical analysis
For dichotomous outcomes, the relative risk (RR) and 95%
confidence interval (CI) were calculated. For continuous out-
comes, the mean difference (MD) and 95% CI was calculated.
The effect estimates were summarized using random effects
analysis. The heterogeneity was evaluated using the Cochrane
chi-squared (v2) test on N  1 degrees of freedom, with an
alpha of 0.05 used for statistical significance and with the I2 test
with 95% CI. We considered low heterogeneity as an I2 value
<25%, moderate heterogeneity as an I2 value of 26–74% and
important heterogeneity as an I2 value 75%. For the meta-
regression analysis, P < 0.05 was considered significant. All
statistical analyses were performed using Review Manager,
version 5.20 and Comprehensive Meta-Analysis software, ver-
sion 2.
RESULTS
Our original search yielded 1089 articles. Based on titles and ab-
stracts, 819 citations were excluded. Based on full-text assessment
of the remaining 270 articles, 9 trials reported in 11 references
were included in the final analysis. Details of the reasons for in-
clusion and exclusion are provided in Figure 1. Of the included
studies, seven were RCTs [21–27] and four were post hoc analyses
of the following RCTs: RENAAL [28], IDNT [29], ALLHAT [30]
and CASE-J [31]. Overall, the entire meta-analysis comprised
9797 participants (data were extracted only once when reports
were available both as an RCT and as a post hoc analysis if there
was more than one publication of the same trial).
Study characteristics
There were five trials that compared ACEIs [21–24, 30] with
placebo or with other antihypertensive treatments. Of these,
four studies enrolled only patients with type 2DM [21–24],
while one study [30] was conducted in a mixed population with
33.3% of patients having type 2DM. Six trials used an ARB [25–
29, 31]; of these, five studies enrolled only patients with type
2DM [25–29] and one study [31] included a mixed population
with 48.2% of patients having type 2DM (Table 1). We did not
find any study using direct renin inhibitors as monotherapy in
patients with DM and moderate to advanced CKD. Overall,
there were two studies that included mixed populations of both
patients with and without diabetes, while the remaining nine
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|included only patients with diabetes. All studies except one
(ALLHAT) [30] included patients who had some degree of pro-
teinuria at baseline—most studies reporting values of 1 g/day.
For the ALLHAT study, this information was not reported [30].
Of the five studies investigating ACEIs, there were three stud-
ies comparing ACEIs with placebo [22–24] and two studies com-
paring ACEIs with other antihypertensive drugs (amlodipine,
nitrendipine, chlorthalidone) [21, 30]. Of the six studies investi-
gating ARBs, two studies compared ARBs with placebo [26, 28],
two studies compared ARBs with other antihypertensive drugs
(amlodipine) [27, 31] and two studies [25, 29] compared ARBs
versus a two-arm control group (placebo and other antihyperten-
sive treatment) (Table 1). The ACEI studies used, in general, min-
imum tomoderate doses of the study drug: 2.5mg/day benazepril
[22], 5mg/day ramipril [21], 20mg/day fosinopril [23], 4mg/day
perindopril [24]. Only one trial [30] used the maximum dosage
(40mg/day lisinopril). All of the ARB studies except one used the
maximum doses of the intervention drug: 100mg/day losartan
[26–28], 300mg/day irbesartan [25, 29], but only 12mg/day can-
desartan [31].
Quantitative analysis
Comparing ACEIs/ARBs with placebo/other antihyperten-
sive treatment, the evaluated outcomes showed the following
results:
(i) All-cause mortality: analysing the overall population, we
did not ﬁnd any signiﬁcant difference between the two
groups for this outcome [four studies, 5309 participants,
RR¼ 0.97 (95% CI 0.85–1.10)] and no heterogeneity
(v2 ¼ 1.38; I2 ¼ 0%) (Figure 2).
(ii) Cardiovascular mortality: we found only two studies re-
porting data for this outcome. No difference was found
between the intervention and control groups [two stud-
ies, 3748 participants, RR¼ 1.03 (95% CI 0.75–1.41)],
with moderate heterogeneity (v2 ¼ 3.49; I2 ¼ 43%)
(Figure 2).
(iii) Non-fatal cardiovascular events: in the overall popula-
tion there was a trend towards a favourable effect esti-
mate for the ACEI/ARB group, with a 10% reduction in
the risk of developing non-fatal CV events [three stud-
ies, 6138 participants, RR¼ 0.90 (95% CI 0.81–1.00)]
with no heterogeneity (v2 ¼ 0.54; I2 ¼ 0%) (Figure 3).
(iv) Renal outcomes: for the composite dichotomous out-
come need for RRT/doubling of serum creatinine, we
found in the overall population a 19% risk reduction in
favour of the intervention arm [ﬁve studies, 5202 par-
ticipants, RR ¼ 0.81 (95% CI 0.70–0.92)] with no het-
erogeneity (v2 ¼ 2.11; I2 ¼ 0%) (Figure 4). When
analysing diabetic patients only, we found a consistent
protective effect for the RAAS-blocking therapy, with a
22% reduction in the risk for the composite dichotom-
ous outcome need for RRT/doubling of serum creatin-
ine [four studies, 3314 participants, RR ¼ 0.78 (95% CI
0.67–0.90)] and no heterogeneity (v2 ¼ 0.04; I2 ¼ 0%)
(Figure 4).
For the continuous outcome of change in eGFR/
CrCl values, we did not ﬁnd a difference in the effect es-
timates between the groups [four studies, 2074 partici-
pants, MD¼0.09 (95% CI 2.75–2.57)] in the overall
group. Of note, there was moderate heterogeneity that
might be explained by the variance in the different tech-
niques used by each study for renal function assessment
and by using different time points for renal function as-
sessment for this outcome (v2¼ 12.64; I2¼ 68%)
(Figure 5).
FIGURE 1: Flow chart of the search strategy and inclusion and exclusion criteria.
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FIGURE 2: All-cause mortality and CV mortality: ACEIs/ARBs versus placebo/other antihypertensive treatment.
FIGURE 3: Non-fatal CV events: ACEIs/ARBs versus placebo/other antihypertensive treatment.
FIGURE 4: Need for RRT/doubling of serum creatinine: ACEIs/ARBs versus placebo/other antihypertensive treatment.
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(v) Adverse events: only two studies, conducted in patients
with DM, reported data for the total number of adverse
events and found no difference between groups [two
studies, 1822 participants, RR¼ 1.05 (95% CI 0.89–
1.25)] (Figure 6). A trend towards a higher overall rate
of serious adverse events was observed in individuals
with CKD, independent of the intervention group, as re-
ported by the ADVANCE authors [24].
Subgroup analysis and investigation for sources of
heterogeneity
We planned to analyse the variability in effect size caused by
studies comparing ACEIs/ARBs versus placebo or versus other
antihypertensive medications to explore whether the effect is
attributed to the antihypertensive effect itself or whether
ACEIs/ARBs have a protective effect on top of their blood pres-
sure–lowering effect. However, in reality, only one study per-
formed a separate analysis for ACEIs/ARBs versus placebo (the
IDNT trial); for all the other studies, it was impossible to extract
data of RAAS-blocking agents versus placebo, as the placebo
arm allowed the use of antihypertensive medication except
RAAS-blocking agents.
We also performed a subgroup analysis stratified by the type
of RAAS agent used in the intervention arm versus controls.
When trials using ACEIs as the intervention were evaluated
separately, data could be analysed only for the all-cause mortal-
ity outcome, showing no difference between the ACEI and con-
trol groups [two studies, 2081 participants, RR¼ 0.88 (95% CI
0.70–1.11)] (Supplementary Figure S7).When studies were ana-
lysed for ARBs as the intervention, there was a 22% reduction in
the risk of reaching the composite outcome of need for RRT/
doubling of serum creatinine [two studies, 3228 participants,
RR¼ 0.78 (95% CI 0.67–0.90)] (Supplementary Figure S2). In
this subgroup analysis of studies using ARBs as an intervention,
we did not find a difference for the outcomes all-cause mortality
and non-fatal cardiovascular events [two studies, 3228
participants, RR¼ 1.01 (95% CI 0.87–1.17) and two studies,
3105 participants, RR¼ 0.91 (95% CI 0.80–1.03), respectively]
(Supplementary Figures S3 and S4).
Other subgroup analysis was intended, stratifying patients
according to CKD stages (eGFR 45 versus 45–60mL/min/
1.73 m2). However, it could not be performed, as the included
studies did not state the exact number of patients for each CKD
stage, asserting only the CKD stages 3–5 status of the
participants.
For the majority of outcomes there was no heterogeneity
present. The only outcomes where we found moderate hetero-
geneity were the cardiovascular mortality outcome (I2¼ 43%)
and the change in eGFR/CrCl outcome (I2¼ 68%). Due to the
small number of included studies, there was no possibility to
further explore possible sources of heterogeneity in these
outcomes.
Finally, we performed a univariate random-effects meta-re-
gression analysis. We found no difference in the effect estimates
of RAAS-blocking agents on the dichotomous composite out-
come of need for RRT/doubling of serum creatinine (P¼ 0.24;
Q¼ 1.35; df¼ 1.00) when accounting for studies including
<100% of patients with DM (Supplementary Figure S5).
Qualitative analysis
Only a small number of studies reported data for further
relevant renal outcomes and adverse events. More specifically,
changes in CrCl and/or eGFR (mL/min/1.73 m2) from baseline
values were reported by only two studies: Tong et al. [23],
weekly changes in CrCl; and Guo et al. [27], monthly evalu-
ations during the entire follow-up period in eGFR. There was a
striking lack of data reported onmajor adverse events: the num-
ber of cases that developed hyperkalaemia during the study
period were reported by only one study [25], changes in baseline
potassium values were not reported by any of the included stud-
ies and potassium values at the end of treatment were reported
by two studies, Suzuki et al. [22] (data for only the intervention
FIGURE 6: Total number of reported adverse events: ACEIs/ARBs versus placebo/other antihypertensive treatment.
FIGURE 5: eGFR/CrCl (ml/min/1.73 m2), end-of-treatment values: ACEIs/ARBs versus placebo/other antihypertensive treatment.
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group) and Tong et al. [23]. Also, the specific number of pa-
tients that developed hypotension throughout the study period
was reported by one study [24]. In the majority of the studies,
adverse events were addressed either as part of composite end-
points or they were not reported at all.
Quality assessment was performed for all 11 studies, which
reported data on the nine included trials (RENAAL and IDNT
trials reported different outcomes in different references).
Overall, the quality of the included studies was suboptimal. For
seven studies, the randomization was unclear [21–23, 26–28,
30] and was at low risk of bias in four studies [24, 25, 29, 31].
Allocation concealment was unclear for all of the included stud-
ies. Blinding of the patients and personnel was unclear for nine
studies [21–29] and was at low risk of bias for two studies [30,
31]. Attrition bias was found to be low for nine studies [22–29,
31] and high for two studies [21, 30]. Nevertheless, selective re-
porting was high for the majority of the trials, except for the two
IDNT post hoc analyses [25, 29] and the ADVANCE post hoc
study [24]. Also, 73% of the included studies were considered as
having a high risk of bias on other bias domains (funding bias
[23–26, 28–31], early discontinuation for the RENAAL trial and
post hoc analysis [26, 28] and imbalance in baseline characteris-
tics [24]) (Supplementary Figures S6 and S7). Results were
largely similar in the sensitivity analysis when excluding trials
with a high risk of bias. Publication bias was assessed for all-
cause mortality, cardiovascular mortality and need for RRT/
doubling of serum creatinine, showing an unequal distribution
of the studies, consistent with possible bias regarding small sam-
ple size and both negative and positive studies (Supplementary
Figures S8 and S9).
The GRADE quality of evidence assessment showed that on
all outcomes we had moderate (all-cause mortality and need for
RRT/doubling of serum creatinine) and low quality of evidence
(CV mortality, non-fatal CV events and total number of re-
ported adverse event outcomes) (Table 2).
DISCUSSION
We conducted a systematic review and meta-analysis to investi-
gate the alleged beneficial impact and safety of RAAS-blocking
agents on cardiovascular and renal outcomes in the setting of
patients with DM and CKD stages 3–5 or eGFR<45mL/min/
1.73 m2). Overall, our results included nine studies (n¼ 9797
participants with CKD stages 3b–5) reporting data for this
growing population. There was no difference between the
RAAS-blocking agents and control groups regarding all-cause
or cardiovascular mortality. There was a trend for a favourable
effect for RAAS-blocking agents for non-fatal cardiovascular
events and a lower risk for the composite outcome of need for
RRT/doubling of serum creatinine when RAAS-blocking agents
were used. It was not possible, however, to assess whether this
effect was due to better control of hypertension or to the RAAS
inhibition per se. Also, regarding the benefits of ACEI versus
ARBIs on renal and cardiovascular mortality, there are insuffi-
cient data, as only three trials used a head-to-head comparison
between these two types of agents (DETAIL, ONTARGET,
ORIENT) [32–35], suggesting an overall insignificant difference
between ACEIs and ARBs in patients with diabetic nephropathy
stages 3b–5.
Although there are several previously published meta-
analyses and systematic reviews evaluating the effects of RAAS-
blocking agents in patients with diabetes [15, 16, 36–41], none
focused on patients with advanced CKD stages 3b–5. One of the
meta-analyses evaluated outcomes with use of renin–angioten-
sin system (RAS) blockers compared with other antihyperten-
sive agents in patients with diabetes. When compared with
other antihypertensive agents, RAS blockers were associated
with a similar risk of death, cardiovascular death or major car-
diovascular events. The authors concluded that in people with
diabetes, RAS blockers are not superior to other antihyperten-
sive drugs at reducing the risk of hard cardiovascular and renal
endpoints [15]. However, only end-stage renal disease (ESRD)
was evaluated as an outcome, whereas doubling of serum cre-
atinine was not considered a ‘hard’ renal endpoint. No sub-
group analysis was in people with diabetic nephropathy.
Catala-Lopez et al. [36] published a network meta-analysis
in adults with diabetes and focused on the comparisons of dif-
ferent RAS blockers. They showed similar effects of ACEIs and
ARBs on major cardiovascular and renal outcomes [36]. No im-
pact of CKD as a comorbidity or impact of the level of eGFR
was reported.
A different network meta-analysis of randomized trials com-
paring blood pressure–lowering agents in adults with diabetic
Table 2. Summary of ﬁndings
Outcome Trials reporting more than one
event/total no. of
trials included
No. of patients
included
Median
treatment
duration
(weeks)
Relative
effect
95% CI Quality of evidence*
1. All-cause mortality (overall) 3/4 5309 135.6 0.97 0.85–1.10 Moderate
2. CV mortality (only diabetics) 2/2 3748 165.6 1.03 0.75–1.41 Low
3. Non-fatal CV events (overall) 3/3 138 161.6 0.90 0.81–1.00 Low
4. Need for RRT/doubling of
serum creatinine (overall)
3/5 5202 139.5 0.81 0.70–0.92 Moderate
5. eGFR/CrCl (mL/min/1.73 m2),
end of treatment (overall)
4/4 2074 120.4 0.09 2.75–2.57 Very low
6. Total no. of reported adverse
events (overall)
2/2 1822 110.4 1.05 0.89–1.25 Low
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|kidney disease found that no drug regimen was more effective
than placebo for reducing all-cause mortality. Only an ARB
(alone or combined with an ACEI) was significantly better than
placebo for prevention of ESKD [16]. However, most of this ef-
fect was attributed to studies comparing RAAS blockade to pla-
cebo, and the evidence evaluating head-to-head comparisons or
other combinations was low.
Finally, a different meta-analysis found that after stratifica-
tion by type of RAAS-blocking agent, only ACEI and not ARB
treatment reduced the risk of all-cause and cardiovascular mor-
tality in patients with DM [41]. In the population with DM and
CKD stages 3b–5 we could not confirm these results, as for this
subpopulation there were mainly studies using ARBs as the
intervention (with a cumulative weight of 76.2). Thus the ab-
sence of a positive effect on mortality by ACEIs in our meta-
analysis should not be considered as conflictive with the general
literature.
There are several major differences between these previous
reports (discussed above) and our current meta-analysis. First,
we were able to include significantly more trials, some of them
published only recently [23, 24, 27, 30, 31]. Second, we allowed
studies comparing RAAS-blocking agents to placebo as well as
to other antihypertensive treatments, and most importantly, we
focussed on patients with diabetes and CKD stages 3–5.
We confirm and extend results from a recent prospective
study assessing the effectiveness and safety of ACEI/ARB treat-
ment in 28 497 adults with late, pre-dialysis, stage 5 CKD—53%
of these patients had diabetes [42]. The use of ACEIs/ARBs was
associated with a lower risk for long-term dialysis [hazard ratio
(HR)¼ 0.94 (95% CI 0.91–0.97)] and for the composite out-
come ‘long-term dialysis or death’ [HR¼ 0.94 (95% CI 0.92–
0.97)].
Based on the evidence included in this meta-analysis and re-
views mentioned above, the European Best renal Practice
Diabetes Guideline Development Group recommended that
adults with CKD stage 3b or higher (eGFR<45mL/min/1.73
m2 or on dialysis) and diabetes who have a cardiovascular indi-
cation (heart failure, ischaemic heart disease) should be treated
with an ACEI at the maximally tolerated dose (1B) [18]. The
guideline development group suggest an RCT on the impact of
on mortality, cardiovascular outcomes and evolution to ESRD
withdrawing or maintaining RAAS inhibitors in patients al-
ready taking them for a cardiac indication when their CKD pro-
gresses to an eGFR<45mL/min/1.73 m2.
Fortunately, results of an ongoing trial may be available in
the future [43]. The STOP-ACEi trial (trial registration: current
controlled trials, ISRCTN62869767), an investigator-led multi-
centre, open-label, randomized controlled clinical trial of 410
participants with advanced (stage 4 or 5) progressive CKD
receiving ACEIs, ARBs or both. Patients will be randomized in
a 1:1 ratio to either discontinue ACEIs, ARBs or a combination
of both (experimental arm) or continue ACEIs, ARBs or com-
bination of both (control arm). The results of this trial will show
whether discontinuation of ACEIs/ARBs can improve or stabil-
ize renal function in patients with advanced progressive CKD.
There are several limitations to the conclusions of our meta-
analysis that are inherent to the studies included. First, it should
be emphasized that the degree of renal impairment can be an
important effect modifier for hard endpoints in patients with
diabetic nephropathy. Most RCTs evaluating relevant cardio-
vascular and renal outcomes in patients with diabetes do not in-
clude patients with CKD stages 3b–5. In our current meta-
analysis, none of the studies included CKD stages 4–5.
Although in the IDNT and RENAAL study serum creatinine
was 1.66 0.5mg and 1.96 0.5mg, respectively, whereas in
ADVANCE it was stipulated that 2000 patients had an
eGFR<60mL/min,1.73 m2, we do not know how many pa-
tients had an eGFR<45mL/min/1.73 m2. As such, our analysis
does not allow a firm conclusion on the effect of RAAS inhibi-
tors in patients with diabetes and CKD stages 4–5. It can be
postulated that any potential beneficial effect would be lower
and adverse effects such as hyperkalaemia would be more
prevalent, but data to support this are lacking. Another limita-
tion is related to the influence of proteinuria. Most of the
included studies were done on patients with medium to severe
proteinuria at baseline and we believe that our results cannot be
extrapolated to patients without proteinuria. Also, due to a lack
of sufficient data, we were unable to perform a subgroup ana-
lysis adjusting on the level of proteinuria and explore the impact
of proteinuria on the outcomes.
It is unclear how far the results of our meta-analysis may be
generalized to the overall population of patients with diabetes
and advanced renal impairment not due to diabetic nephrop-
athy. A recent systematic review found that a substantial por-
tion of patients with diabetes and kidney disease do not have
diabetic nephropathy, but have some other primary kidney dis-
ease [44]. In addition, in IDNT, renovascular disease was an ex-
clusion criterion, whereas in ADVANCE, patients had a trial
with perindopril before inclusion; in RENAAL, only tolerant
patients were included. As such, all patients who could poten-
tially be harmed or have a deterioration of their kidney func-
tion by the use of RAAS-blocking agents were excluded before
the start of the trial (selection bias).
In most studies there is a residual difference in blood pres-
sure control between the RAAS-blocking group and the control
group. It is thus uncertain howmuch of the effect is due to a dif-
ference in achieved blood pressure control rather than a pure
RAAS-blocking effect.
The most important strength of this meta-analysis is that it
is based on a systematic search of medical databases, data ex-
traction and analysis of all current and the most recent informa-
tion on the effects of RAAS-blocking agents in the specific
population of patients with CKD stages 3b–5 and diabetes. To
our knowledge, this is the first time a meta-analysis has been
done in this specific population.
CONCLUSION
In conclusion, we found in this meta-analysis that treatment
with RAAS-blocking agents, either ACEIs or ARBs, has favour-
able effects on renal outcomes in patients with DM and CKD
stages 3–5, but only if the renal outcome is assessed as a com-
posite outcome of need for RRT/doubling of serum creatinine
and not when it was expressed as the evolution of GFR.
Unfortunately, a lack of data precludes making firm conclusions
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|on their impact on mortality outcomes and also hampers inter-
pretation of the differential impact of the class of RAAS-
blocking agent. There is a considerable risk of selection bias in
the included studies, focussing on patients with true diabetic
nephropathy and excluding patients with comorbidities known
to lead to poor tolerance of RAAS-blocking agents.
Furthermore, there is an underreporting of potential adverse
events, whereas our population of interest is at increased risk of
these side effects.
As such, the question of whether to prescribe or withhold
RAAS-blocking agents in patients with DM and CKD stages 3–
5 cannot be answered with confidence based on the available
evidence.
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